Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 234 results for "Multiple Myeloma (MM)".

Thumbnail for New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

MM - 326

New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

Thumbnail for Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

MM - 338

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani

Previous 1...13 14 15 16 17 18 19...26 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Poster Presenter: Saad Z Usmani

$Thumbnail for Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk$

MM - 349

Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk

Kaci Ernst

Poster Presenter: Kaci Ernst

Thumbnail for Extraosseous Plasmacytoma: Real-World Outcomes of a Rare Plasma Cell Neoplasm using the SEER Database

MM - 351

Extraosseous Plasmacytoma: Real-World Outcomes of a Rare Plasma Cell Neoplasm using the SEER Database

Vidushi Reddy Gillela

Poster Presenter: Vidushi Reddy Gillela

Thumbnail for Prognostic Factors for Castleman Disease Include Tumor Diameter, Lymphocyte Count, Estimated Glomerular Filtration Rate, and Low-Density Lipoprotein Cholesterol: A Retrospective Cohort Study

MM - 369

Prognostic Factors for Castleman Disease Include Tumor Diameter, Lymphocyte Count, Estimated Glomerular Filtration Rate, and Low-Density Lipoprotein Cholesterol: A Retrospective Cohort Study

Kezhi Huang

Poster Presenter: Kezhi Huang

Thumbnail for Severe Opportunistic Infection Signals Associated With BCMA- and GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma

MM - 374

Severe Opportunistic Infection Signals Associated With BCMA- and GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma

Alexander Den Boef

Poster Presenter: Alexander Den Boef

Thumbnail for Cytomegalovirus Reactivation and Tissue-Invasive CMV Disease Associated With Bispecific Antibodies in Multiple Myeloma

MM - 375

Cytomegalovirus Reactivation and Tissue-Invasive CMV Disease Associated With Bispecific Antibodies in Multiple Myeloma

Barrie Clark

Poster Presenter: Barrie Clark

Thumbnail for Baseline Risk Modifiers for Multiple Myeloma Following Herpes Zoster: A Multicenter Retrospective Cohort Study

MM - 386

Baseline Risk Modifiers for Multiple Myeloma Following Herpes Zoster: A Multicenter Retrospective Cohort Study

Aditya Anand

Poster Presenter: Aditya Anand

Thumbnail for National Trends in Multiple Myeloma-Associated Pneumonia Mortality Among Adults Aged =25 Years, United States: a CDC Wonder Analysis of 1999-2024

MM - 387

National Trends in Multiple Myeloma-Associated Pneumonia Mortality Among Adults Aged =25 Years, United States: a CDC Wonder Analysis of 1999-2024

Madho Mal

Poster Presenter: Madho Mal

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors